Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VRC-WNVDNA020-00-VP
- Development stage
- Phase 1
- Lead developer
- Vaccine Research Center
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
VRC-WNVDNA020-00-VP is a second-generation DNA vaccine candidate developed for the prevention of West Nile Virus (WNV) infection. The vaccine consists of a single, closed, circular plasmid DNA macromolecule (VCL-8111) engineered to express the prM and E proteins of the WNV envelope glycoprotein. These sequences are derived from the NY99 human WNV isolate. The plasmid uses a modified CMV/R promoter, which includes regulatory elements from HTLV-1 to enhance transcription and posttranscriptional events, resulting in improved protein expression and immunogenicity compared to earlier constructs. Upon administration, in vitro expression leads to formation of noninfectious subviral particles (SVPs), stimulating an immune response without risk of generating infectious virions. The vaccine was produced under Good Manufacturing Practices by bacterial fermentation with kanamycin selection[1]. Early clinical trials demonstrated that it induces neutralizing antibodies against WNV in healthy adults[3].
- Other names
- VCL-8111VCL8111VCL 8111
02
Targets
WNV E (West Nile virus envelope protein)E (Tick-borne encephalitis virus envelope protein)prM (Zika virus precursor membrane protein)
Beyond the preview
Go deeper on VRC-WNVDNA020-00-VP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VRC-WNVDNA020-00-VP.